

Dated: August 20, 2007.

**Maryam I. Daneshvar,**

*Acting Reports Clearance Officer, Centers for Disease Control and Prevention.*

[FR Doc. E7-16920 Filed 8-24-07; 8:45 am]

BILLING CODE 4163-18-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### National Center for Health Statistics (NCHS), Classifications and Public Health Data Standards Staff, Announces the Following Meeting

*Name:* ICD-9-CM Coordination and Maintenance Committee meeting.

*Time and Date:* 8:30 a.m.-6 p.m., September 27-28, 2007.

*Place:* Centers for Medicare and Medicaid Services (CMS) Auditorium, 7500 Security Boulevard, Baltimore, Maryland.

*Status:* Open to the public.

*Purpose:* The ICD-9-CM Coordination and Maintenance (C&M) Committee will hold its final meeting of the 2007 calendar year cycle on Thursday and Friday, September 27-28, 2007. The C&M meeting is a public forum for the presentation of proposed modifications to the International Classification of Diseases, Ninth-Revision, Clinical Modification.

#### Matters To Be Discussed

Tentative agenda items include:

- Androgen insensitivity
- Carcinoid tumors/neuroendocrine tumors
- Decubitus ulcer expansion
- Eosinophilic disorders
- Fetal medicine
- Functional incontinence
- Heparin-induced thrombocytopenia
- Isolated systolic hypertension
- Keratitis (Acanthamoeba and Fusarium)
- Leukemia in relapse
- Necrotizing enterocolitis
- Retrolental fibroplasia
- Secondary diabetes
- Ventilator-associated pneumonia
- Wound disruption
- Addenda (Diagnoses)
- ICD-10-CM Update
- Non-invasive positive pressure ventilation
- Laparoscopic colectomy
- Laparoscopic deployed inguinal hernia repair mesh
- Oversewing of atrial appendage
- Bi-ventricular replacement
- Intra-aneurysm sac pressure
- Direct aqueous oxygen infusion therapy
- Kyphoplasty

- Intravascular chemography
- Intravascular pressure measurement
- Percutaneous tracheostomy
- Repair of the annulus fibrosus
- Surgical gel implantation

#### Addenda (Procedures)

ICD-10-Procedure Classification System (PCS) update.

#### FOR FURTHER INFORMATION CONTACT:

Amy Blum, Medical Systems Specialist, Classifications and Public Health Data Standards Staff, NCHS, 3311 Toledo Road, Room 2402, Hyattsville, Maryland 20782, e-mail [alb8@cdc.gov](mailto:alb8@cdc.gov), telephone 301-458-4106 (diagnosis), Mady Hue, Health Insurance Specialist, Division of Acute Care, CMS, 7500 Security Blvd., Baltimore, Maryland, 21244, e-mail [marilu.hue@cms.hhs.gov](mailto:marilu.hue@cms.hhs.gov), telephone 410-786-4510 (procedures).

*Notice:* Because of increased security requirements CMS has instituted stringent procedures for entrance into the building by non-government employees. Persons without a government I.D. will need to show an official form of picture I.D., (such as a drivers license), and sign-in at the security desk upon entering the building.

Those who wish to attend a specific ICD-9-CM C&M meeting in the CMS auditorium must submit their name and organization for addition to the meeting visitor list. Those wishing to attend the September 27-28, 2007 meeting must submit their name and organization by September 20, 2007 for inclusion on the visitor list. This visitor list will be maintained at the front desk of the CMS building and used by the guards to admit visitors to the meeting. Those who attended previous ICD-9-CM C&M meetings will no longer be automatically added to the visitor list. You must request inclusion of your name prior to each meeting you attend.

Register to attend the meeting on-line at: <http://www.cms.hhs.gov/apps/events/>.

*Notice:* This is a public meeting. However, because of fire code requirements, should the number of attendants meet the capacity of the room, the meeting will be closed.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC

and the Agency for Toxic Substances and Disease Registry.

**Diane C. Allen,**

*Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).*

[FR Doc. E7-16903 Filed 8-24-07; 8:45 am]

BILLING CODE 4160-18-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. 2007N-0304]

#### Preparation for International Conference on Harmonization Meetings in Yokohama, Japan; Public Meeting; Correction

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice of meeting; correction.

**SUMMARY:** The Food and Drug Administration (FDA) is correcting a notice that appeared in the **Federal Register** on August 13, 2007 (72 FR 45250). The document announced a public meeting entitled "Preparation for ICH meetings in Yokohama, Japan" to provide information and receive comments on the International Conference on Harmonization (ICH) as well as the upcoming meetings in Yokohama, Japan. The topics to be discussed are the topics for discussion at the forthcoming ICH Steering Committee Meeting. The purpose of the meeting is to solicit public input prior to the next Steering Committee and Expert Working Groups meetings in Yokohama, Japan, October 27 through November 1, 2007, at which discussion of the topics underway and the future of ICH will continue.

**FOR FURTHER INFORMATION CONTACT:** For information regarding this notice and the original notice: Tammie Bell, Office of the Commissioner, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, e-mail: [Tammie.Bell2@fda.hhs.gov](mailto:Tammie.Bell2@fda.hhs.gov), FAX: 301-827-0003.

**SUPPLEMENTARY INFORMATION:** In FR Doc. E7-15803, appearing on page 45250 in the **Federal Register** of Monday, August 13, 2007, the following correction is made:

1. On page 45250, in the third column, the second full paragraph is corrected to read "Interested persons may present data, information, or views orally or in writing, on issues pending at the public meeting. Oral presentations from the public will be scheduled between approximately 2:30

p.m. and 3 p.m. Time allotted for oral presentations may be limited to 10 minutes. Those desiring to make oral presentations should notify the contact person by October 2, 2007, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses, phone number, fax, and e-mail of proposed participants, and an indication of the approximate time requested to make their presentation.”

Dated: August 20, 2007.

**Jeffrey Shuren,**

*Assistant Commissioner for Policy.*

[FR Doc. E7-16892 Filed 8-24-07; 8:45 am]

**BILLING CODE 4160-01-S**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Health Resources and Services Administration

#### Advisory Commission on Childhood Vaccines; Notice of Meeting Cancellation

Notice is hereby given of the cancellation of the Advisory Commission on Childhood Vaccines (ACCV) Meeting, September 7, 2007, 9 a.m. to 5 p.m., Parklawn Building (and via audio conference call), Conference Rooms G & H, 5600 Fishers Lane, Rockville, MD 20857, which was published in the **Federal Register** on August 15, 2007, 72 FR 45822-45823.

Dated: August 21, 2007.

**Alexandra Huttinger,**

*Acting Director, Division of Policy Review and Coordination.*

[FR Doc. E7-16868 Filed 8-24-07; 8:45 am]

**BILLING CODE 4165-15-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material,

and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Arthritis and Musculoskeletal and Skin Diseases Special Emphasis Panel; Tissue Engineering and Regenerative Medicine.

*Date:* September 11, 2007.

*Time:* 1 p.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, One Democracy Plaza, 6701 Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference Call).

*Contact Person:* Charles H. Washabaugh, PhD, Scientific Review Administrator, Review Branch, NIAMS/NIH, 6701 Democracy Blvd., Room 816, Bethesda, MD 20892, 301 451-4838, [washabac@mail.nih.gov](mailto:washabac@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.846, Arthritis, Musculoskeletal and Skin Diseases Research, National Institutes of Health, HHS).

Dated: August 15, 2007.

**Jennifer Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 07-4158 Filed 8-24-07; 8:45 am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Office of the Director, National Institutes of Health; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Recombinant DNA Advisory Committee.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

*Name of Committee:* Recombinant DNA Advisory Committee.

*Date:* September 17-18, 2007.

*Time:* September 17, 2007, 8 a.m. to 12 p.m.

*Agenda:* The Recombinant DNA Advisory Committee will review and discuss elected human gene transfer protocols as well as related data management activities. There will also be a discussion about new clinical safety information.

*Place:* National Institutes of Health, Natcher Building, 45 Center Drive, Auditorium, Bethesda, MD 20892.

*Time:* September 17, 2007, 12:30 p.m. to 6 p.m.

*Agenda:* Continued.

*Place:* National Institutes of Health, Building 31, Floor 5C, 31 Center Drive, Conference Room 6, Bethesda, MD 20892.

*Time:* September 18, 2007, 8 a.m. to 12 p.m.

*Agenda:* Continued.

*Place:* National Institutes of Health, Building 31, Floor 6C, 31 Center Drive, Conference Room 6, Bethesda, MD 20892.

*Contact Person:* Laurie Lewallen, Advisory Committee Coordinator, Office of Biotechnology Activities, National Institutes of Health, 6705 Rockledge Drive, Room 750, Bethesda, MD 20892-7985, 301-496-9838, [lewallla@od.nih.gov](mailto:lewallla@od.nih.gov).

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Information is also available on the Institute's/Center's home page: <http://www4.od.nih.gov/oba/>, where an agenda and any additional information for the meeting will be posted when available.

OMB's "Mandatory Information Requirements for Federal Assistance Program Announcements" (45 FR 39592, June 11, 1980) requires a statement concerning the official government programs contained in the Catalog of Federal Domestic Assistance. Normally NIH lists in its announcements the number and title of affected individual programs for the guidance of the public. Because the guidance in this notice covers virtually every NIH and Federal research program in which DNA recombinant molecule techniques could be used, it has been determined not to be cost effective or in the public interest to attempt to list these programs. Such a list would likely require several additional pages. In addition, NIH could not be certain that every Federal program would be included as many Federal agencies, as well as private organizations, both national and international, have elected to follow the NIH Guidelines. In lieu of the individual program listing, NIH invites readers to direct questions to the information address above about whether individual programs listed in the Catalog of Federal Domestic Assistance are affected.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research General; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from